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Background
CT angiography (CTA) is standard for assessment of
arterial access anatomy prior to transcatheter aortic
valve replacement (TAVR) procedures [1]. However,
TAVR candidates are generally elderly with a higher
prevalence of renal impairment than the general popula-
tion and it is desirable to eliminate the use of iodinated
contrast prior to catheterization because of the severe
consequences of post-procedural renal failure [2].
Further, gadolinium based contrast agents may be pro-
blematic in renal impairment because of the perceived
risk of NSF. We hypothesized that ferumoxytol may be
a suitable alternative to CTA and Gd contrast enhanced
MRA in these patients.
Methods
Following informed consent and with approval from our
IRB, we performed ferumoxytol enhanced MRA
(FEMRA) for assessment of arterial access anatomy
prior to TAVR in 20 patients (M/F = 15/5, mean age
84.5 yrs (+/- 8) with aortic stenosis and renal impair-
ment (eGFR < 30 mls /m2.mn). FEMRA was performed
at 3.0T in 15 patients and at 1.5T in 5, using a total
dose of 4 mg /kg. Two patients had cardiac pacemakers.
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First pass and steady state FEMRA was performed in 16
patients and steady state imaging only in 4. The field of
view extended from the neck to the proximal thighs in
two overlapping stations. Images were post-processed
with MIP and Volume Rendering.
Results
In all cases, FEMRA produced highly diagnostic studies,
which formed the basis for confident TAVR planning.
Figure 1 shows a volume rendered FEMRA study in an
87 year old male who subsequently underwent TAVR.
All patients remained stable throughout the FEMRA
procedures and there were no symptoms or significant
changes in heart rate, blood pressure or blood oxygena-
tion. Both first pass and steady state images were con-
sidered highly diagnostic. 12 patients had successful
TAVR placement via a femoral approach with angio-
graphic confirmation of FEMRA findings. 6 patients
were not considered candidates for a femoral approach
on the basis of FEMRA and had successful trans-apical
placement. 2 patients are pending treatment.
Conclusions
In the current study, FEMRA was diagnostic, practical
and safe at both 3.0T and 1.5T and provided sufficient
information for confident planning of the access route
for TAVR. FEMRA holds promise as an alternative to
CTA and Gd CEMRA in patients with renal impairment.
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